—

Revenue dipped low single digits year over year, but excluding COVID products operational sales rose high single digits. Non-COVID franchises including Eliquis, Prevnar and oncology biosimilars drove top-line growth while cost savings and gross margin expansion lifted adjusted EPS above estimates. Full-year 2026 guidance calls for $2.80–3.00 in adjusted EPS and roughly $5 billion in COVID revenues, with the dividend maintained at current levels. The pipeline was bolstered by the Seagen acquisition and positive Phase 3 PADCEV trial results.

Patent expirations in 2026–2030 threaten blockbuster revenues even as China approval of Pfizer’s new obesity therapy intensifies competition in GLP-1 treatments. Several oncology candidates—from BRAFTOVI regimens to EV-304—are awaiting regulatory clearance in key markets, supported by in-licensing deals, acquisitions and partnerships. US MFN pricing rules and ongoing IP litigation impose legal and pricing constraints, while AI integration in manufacturing reflects evolving Pharma 4.0 supply-chain dynamics.

Investors remain cautious about Pfizer’s near-term challenges from COVID sales declines, patent expirations and pipeline setbacks in the GLP-1 space, but bullish sentiment is rising on its undervaluation, management’s heavy investment in obesity and oncology catalysts expected in 2026, and growing analyst confidence in post-2028 revenue and earnings growth.